ENG/中
老虎证券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息(分红)
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登录
立即注册
Toggle
美股
详情
本页面由Tiger Trade Technology Pte. Ltd.提供服务
Bicara Therapeutics
23.90
-0.4900
-2.01%
盘后:
23.90
0.0000
0.00%
19:30 EDT
成交量:
49.64万
成交额:
1,202.92万
市值:
15.82亿
市盈率:
-7.69
高:
25.56
开:
24.73
低:
23.77
收:
24.39
52周最高:
30.99
52周最低:
10.30
股本:
6,617.29万
流通股本:
5,230.21万
量比:
1.00
换手率:
0.95%
股息:
- -
股息率:
- -
每股收益(TTM):
-3.1097
每股收益(LYR):
-2.5230
净资产收益率:
-41.01%
总资产收益率:
-26.14%
市净率:
3.37
市盈率(LYR):
-9.47
数据加载中...
总览
公司
新闻资讯
公告
美国研究综述-卡迪纳尔健康、卢门图姆控股、公共仓储
路透中文
·
08/12
Bicara Therapeutics发布2026年第二季度进展,宣布战略领导层变动,开启执行与增长新篇章
美股速递
·
08/11
Bicara Therapeutics公司:1500毫克Ficerafusp Alfa联合帕博利珠单抗在1L R/M HPV阴性HNSCC中显示31%的三年总生存率
美股速递
·
05/22
Bicara Therapeutics公布1B期研究结果:展现深度、持久的应答与良好的耐受性安全性特征
美股速递
·
05/22
美国研究综述-爱彼迎、HII、特斯拉
路透中文
·
05/11
Biocon董事长基兰·马祖姆达尔-肖制定五年继任计划,指定侄女为继任者
路透中文
·
05/05
Biocon董事长基兰·马祖姆达尔-肖确定继任人选,这家印度制药公司正筹划领导层交接
路透中文
·
05/05
异动解读 | 启动关键性试验第三阶段,Bicara Therapeutics盘中大涨5.68%
异动解读
·
03/30
异动解读 | Bicara Therapeutics启动关键性试验第三阶段,股价盘前大涨5.55%
异动解读
·
03/30
Bicara Therapeutics启动Fortifi-Hn01关键性试验第三阶段 中期分析预计2027年中进行
美股速递
·
03/30
Bicara Therapeutics超额认购公开发行圆满收官,承销商全额行使额外购股权
美股速递
·
02/27
BUZZ-Bicara Therapeutics 募资 1.5 亿美元后股价上涨
路透中文
·
02/25
Bicara Therapeutics宣布1.5亿美元普通股及预付认股权证公开发行定价
美股速递
·
02/25
Ficerafusp Alfa 2000毫克Q2w方案在1L R/M HPV阴性头颈鳞癌中展现深度持久疗效 并支持开发更低频给药方案
美股速递
·
02/20
Bicara Therapeutics计划开发Ficerafusp Alfa的负荷剂量与三周一次维持方案,待监管审批
美股速递
·
02/20
{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股,新股,港股,A股等全球金融理财产品。新加坡华人最信赖的在线投资平台,现在加入即享低费用,24/5 无时差炒美股投资理财!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/BCAX/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":23.9,"timestamp":1787342400000,"preClose":24.39,"halted":0,"volume":496353,"hourTrading":{"tag":"盘后","latestPrice":23.9,"preClose":23.9,"latestTime":"19:30 EDT","volume":9050,"amount":216300.04,"timestamp":1787355007488,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.020090200902009102,"floatShares":52302133,"shares":66172934,"eps":-3.109661,"marketStatus":"休市中","change":-0.49,"latestTime":"08-21 16:00:00 EDT","open":24.73,"high":25.555,"low":23.77,"amount":12029223.159954,"amplitude":0.073186,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.109661,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":24.39,"preHourTrading":{"tag":"盘前","latestPrice":24.39,"preClose":24.39,"latestTime":"08:45 EDT","volume":3,"amount":73.17,"timestamp":1787316356497,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":23.9,"preClose":23.9,"latestTime":"19:30 EDT","volume":9050,"amount":216300.04,"timestamp":1787355007488,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0006487493527585,"impliedVol":0.4166,"impliedVolPercentile":0.6016},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":52302133,"roa":"-26.14%","roe":"-41.01%","lyrEps":-2.523003,"volumeRatio":1.0006487493527585,"shares":66172934,"dividePrice":0,"high":25.555,"amplitude":0.073186,"preClose":24.39,"low":23.77,"week52Low":10.295,"pbRate":"3.37","week52High":30.99,"institutionHeld":0,"latestPrice":23.9,"eps":-3.109661,"divideRate":0,"volume":496353,"delay":0,"ttmEps":-3.109661,"open":24.73,"prevYearClose":16.83,"prevWeekClose":24.28,"prevMonthClose":27.1,"prevQuarterClose":29.69,"fiveDayClose":24.28,"twentyDayClose":27.02,"sixtyDayClose":21.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"BCAX","fiscalQuarterEnding":"2026/06","expectedEps":-0.77,"name":null,"time":"盘前","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.82},{"market":"US","date":"2026-05-11","symbol":"BCAX","fiscalQuarterEnding":"2026/03","expectedEps":-0.64,"name":null,"time":"盘前","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"pre","actualEps":-0.93},{"market":"US","date":"2026-03-30","symbol":"BCAX","fiscalQuarterEnding":"2025/12","expectedEps":-0.72,"name":null,"time":"盘前","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"盘前","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"盘前","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3125,"buy":0.5,"hold":0.1875,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":16,"updateTime":1787112000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-08-21","current":-7.685725,"percent":0.592975,"low":-22.704836,"twenty":-12.33633,"median":-9.572721,"eighty":-6.915667,"high":-5.144536,"avg":-10.510848,"sd":4.129805,"marketCap":1613957860},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669},{"date":"2026-02-27","current":-8.759817,"twenty":-15.498177,"median":-8.759817,"eighty":-6.531952,"marketCap":1064501760},{"date":"2026-03-06","current":-9.890416,"twenty":-15.312456,"median":-8.853601,"eighty":-6.556096,"marketCap":1201893200},{"date":"2026-03-13","current":-10.269994,"twenty":-15.203584,"median":-8.927397,"eighty":-6.566815,"marketCap":1248019912},{"date":"2026-03-20","current":-10.045455,"twenty":-15.15052,"median":-9.021228,"eighty":-6.577062,"marketCap":1220733688},{"date":"2026-03-27","current":-10.114955,"twenty":-14.98767,"median":-9.07442,"eighty":-6.589163,"marketCap":1229179424},{"date":"2026-04-02","current":-9.728723,"twenty":-14.625375,"median":-9.090377,"eighty":-6.609609,"marketCap":1342077333},{"date":"2026-04-10","current":-10.431089,"twenty":-14.409462,"median":-9.148523,"eighty":-6.631964,"marketCap":1438968770},{"date":"2026-04-17","current":-11.356504,"twenty":-14.321633,"median":-9.207398,"eighty":-6.63974,"marketCap":1566629784},{"date":"2026-04-24","current":-10.839221,"twenty":-14.136826,"median":-9.386913,"eighty":-6.653842,"marketCap":1495270551},{"date":"2026-05-01","current":-10.241261,"twenty":-13.992274,"median":-9.457397,"eighty":-6.668268,"marketCap":1412781895},{"date":"2026-05-08","current":-10.980156,"twenty":-13.748914,"median":-9.551117,"eighty":-6.6946,"marketCap":1514712543},{"date":"2026-05-15","current":-8.624637,"twenty":-13.404917,"median":-9.536519,"eighty":-6.716778,"marketCap":1356784832},{"date":"2026-05-22","current":-8.703992,"twenty":-13.199982,"median":-9.448315,"eighty":-6.737692,"marketCap":1369268567},{"date":"2026-05-29","current":-9.084061,"twenty":-13.028804,"median":-9.388604,"eighty":-6.752117,"marketCap":1429059085},{"date":"2026-06-05","current":-8.524399,"twenty":-12.837909,"median":-9.249533,"eighty":-6.75968,"marketCap":1341015905},{"date":"2026-06-12","current":-8.887762,"twenty":-12.760238,"median":-9.180782,"eighty":-6.769997,"marketCap":1398178268},{"date":"2026-06-18","current":-9.572721,"twenty":-12.640072,"median":-9.17593,"eighty":-6.781418,"marketCap":1505932608},{"date":"2026-06-26","current":-11.001111,"twenty":-12.607001,"median":-9.207398,"eighty":-6.784967,"marketCap":1730639830},{"date":"2026-07-02","current":-12.074492,"twenty":-12.533268,"median":-9.343805,"eighty":-6.786535,"marketCap":1899498766},{"date":"2026-07-10","current":-12.396089,"twenty":-12.533268,"median":-9.434628,"eighty":-6.792442,"marketCap":1950090742},{"date":"2026-07-17","current":-11.52736,"twenty":-12.506498,"median":-9.486153,"eighty":-6.807115,"marketCap":1813426701},{"date":"2026-07-24","current":-11.581656,"twenty":-12.437044,"median":-9.561678,"eighty":-6.833787,"marketCap":1821968204},{"date":"2026-07-31","current":-10.971875,"twenty":-12.407622,"median":-9.577189,"eighty":-6.841301,"marketCap":1726040559},{"date":"2026-08-07","current":-11.489771,"twenty":-12.396924,"median":-9.702195,"eighty":-6.849841,"marketCap":1807513353},{"date":"2026-08-14","current":-8.435699,"twenty":-12.359992,"median":-9.679126,"eighty":-6.875132,"marketCap":1563666430},{"date":"2026-08-21","current":-8.707012,"twenty":-12.33633,"median":-9.572721,"eighty":-6.915667,"marketCap":1613957860}],"updateTime":1787490989523},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658927621","title":"美国研究综述-卡迪纳尔健康、卢门图姆控股、公共仓储","url":"https://stock-news.laohu8.com/highlight/detail?id=2658927621","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658927621?lang=zh_cn&edition=fundamental","pubTime":"2026-08-12 16:08","pubTimestamp":1786522123,"startTime":"0","endTime":"0","summary":"美国研究综述-卡迪纳尔健康、卢门图姆控股、公共仓储路透8月12日-周三,华尔街证券分析师调整了多家在美国上市公司的评级和目标股价,其中包括卡迪纳尔健康、卢门图姆控股和公共仓储。股票按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4S4490GS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTR","BCAX","PSA","ACVA","LBRX","BBIO","USFD","CAVA","MDLN","LEGN","MNST","JBIO","MIDD","SR","WELL","EGGY","TXG","TGT","LOW","ANF","MRCY","LPTH","JAZZ","REIT","AMBQ","RPD","COAG","NTRA","UMAC","LENZ","CVS","CAH","PNW","HD","URBN","BLCK","GAP","CRCL","NEMG","CUBE","HLIO","CANC","MAA","ACM","NEM","CRWV","LITE","EXR","FLUT","SGMT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189357607","title":"Bicara Therapeutics发布2026年第二季度进展,宣布战略领导层变动,开启执行与增长新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1189357607","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189357607?lang=zh_cn&edition=fundamental","pubTime":"2026-08-11 19:31","pubTimestamp":1786447875,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics今日披露其2026年第二季度的业务进展,并同步宣布一系列战略性的领导层调整。此举标志着公司正迈入一个全新的执行与增长阶段。这些变动旨在优化管理架构,为下一阶段的战略推进奠定坚实基础。公司方面表示,此次领导层的过渡是基于对未来发展的深思熟虑,旨在更高效地驱动核心项目,并把握市场机遇。通过引入新的领导视角与经验,Bicara Therapeutics正蓄势待发,准备在充满活力的生物技术领域加速前行,致力于为患者带来突破性的疗法。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168800830","title":"Bicara Therapeutics公司:1500毫克Ficerafusp Alfa联合帕博利珠单抗在1L R/M HPV阴性HNSCC中显示31%的三年总生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=1168800830","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168800830?lang=zh_cn&edition=fundamental","pubTime":"2026-05-22 05:09","pubTimestamp":1779397760,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics公司公布的数据显示,其1500毫克剂量的Ficerafusp Alfa联合帕博利珠单抗,在一线治疗复发/转移性人乳头瘤病毒阴性头颈鳞状细胞癌患者中,取得了31%的三年总生存率结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150998880","title":"Bicara Therapeutics公布1B期研究结果:展现深度、持久的应答与良好的耐受性安全性特征","url":"https://stock-news.laohu8.com/highlight/detail?id=1150998880","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150998880?lang=zh_cn&edition=fundamental","pubTime":"2026-05-22 05:09","pubTimestamp":1779397753,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc 公布的最新1B期临床研究数据揭示,其试验性疗法展现出深度且持久的治疗应答,同时具备耐受性良好的安全性特征。该研究结果进一步支持了该疗法的临床开发潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634403179","title":"美国研究综述-爱彼迎、HII、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2634403179","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634403179?lang=zh_cn&edition=fundamental","pubTime":"2026-05-11 15:29","pubTimestamp":1778484590,"startTime":"0","endTime":"0","summary":"美国研究综述-爱彼迎、HII、特斯拉路透5月11日 - 周一,华尔街证券分析师下调了多家美国上市公司的评级和目标股价,其中包括爱彼迎、HII和特斯拉。股票条目按字母顺序排列。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL4T41O0H2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMDG","HII","AGL","LOAR","FRDU","ABNG","AMDS","BWA","HUBS","AMUU","ANIP","ALB","AMDY","F","CWH","AMYY","FERG","CVS","ATLC","AZTA","THRM","AMPH","FIS","DASH","GNTX","BILL","JBIO","TECH","BCAX","GFS","CAR","GM","IBP","BAM","ESE","GT","ABNB","ARXS","INTU","LEA","LNTH","AMDW","DAMD","FRDD","HWM","AVTX","HTZ","CGON","AMD","DAN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633617992","title":"Biocon董事长基兰·马祖姆达尔-肖制定五年继任计划,指定侄女为继任者","url":"https://stock-news.laohu8.com/highlight/detail?id=2633617992","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633617992?lang=zh_cn&edition=fundamental","pubTime":"2026-05-05 14:46","pubTimestamp":1777963591,"startTime":"0","endTime":"0","summary":"更新版 2-Biocon董事长基兰·马祖姆达尔-肖制定五年继任计划,指定侄女为继任者补充了评论、细节和背景信息Rishika Sadam. 路透5月5日 - Biocon BION.NS 创始人兼董事长基兰·马祖姆达尔-肖周二表示,她计划在未来五年内分阶段进行领导层交接,其侄女克莱尔·马祖姆达尔预计最终将接任董事长一职。“只要我们持有Biocon的大量股份,我就想确保家族的传承能够延续,”马祖姆达尔-肖表示,并补充说她的家族成员一直担任该公司董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL4S41I0DY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633399470","title":"Biocon董事长基兰·马祖姆达尔-肖确定继任人选,这家印度制药公司正筹划领导层交接","url":"https://stock-news.laohu8.com/highlight/detail?id=2633399470","media":"路透中文","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633399470?lang=zh_cn&edition=fundamental","pubTime":"2026-05-05 14:29","pubTimestamp":1777962582,"startTime":"0","endTime":"0","summary":"Biocon董事长基兰·马祖姆达尔-肖确定继任人选,这家印度制药公司正筹划领导层交接\n路透5月5日 - Biocon创始人基兰·马祖姆达尔-肖向路透表示,她计划在未来五年内逐步完成领导层交接,其侄女克莱尔·马祖姆达尔预计将分阶段接任董事长一职。该继任计划最初由商业杂志《财富印度》在对马祖姆达尔-肖的采访中报道 (link)。(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nL4S41I0DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111684845","title":"异动解读 | 启动关键性试验第三阶段,Bicara Therapeutics盘中大涨5.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111684845","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111684845?lang=zh_cn&edition=fundamental","pubTime":"2026-03-30 22:15","pubTimestamp":1774880121,"startTime":"0","endTime":"0","summary":"消息面上,公司已正式启动其核心候选药物Fortifi-Hn01的关键性试验第三阶段。该阶段标志着药物研发进程中的重要里程碑,旨在进一步评估其在头颈癌治疗中的有效性与安全性,这一积极进展显著增强了投资者对公司研发前景的信心。Fortifi-Hn01作为Bicara Therapeutics研发管线中的重点产品,其第三阶段临床试验的推进备受业界关注,若最终结果符合预期,该药物有望为头颈癌患者提供新的治疗选择,并可能为公司带来重要的商业机会。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154155522","title":"异动解读 | Bicara Therapeutics启动关键性试验第三阶段,股价盘前大涨5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154155522","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154155522?lang=zh_cn&edition=fundamental","pubTime":"2026-03-30 19:36","pubTimestamp":1774870598,"startTime":"0","endTime":"0","summary":"消息面上,公司已正式启动其核心候选药物Fortifi-Hn01的关键性试验第三阶段。该阶段标志着药物研发进程中的重要里程碑,旨在进一步评估其在头颈癌治疗中的有效性与安全性,这一积极进展显著增强了投资者对公司研发前景的信心。Fortifi-Hn01作为Bicara Therapeutics研发管线中的重点产品,其第三阶段临床试验的推进备受业界关注,若最终结果符合预期,该药物有望为头颈癌患者提供新的治疗选择,并可能为公司带来重要的商业机会。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178506877","title":"Bicara Therapeutics启动Fortifi-Hn01关键性试验第三阶段 中期分析预计2027年中进行","url":"https://stock-news.laohu8.com/highlight/detail?id=1178506877","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178506877?lang=zh_cn&edition=fundamental","pubTime":"2026-03-30 19:35","pubTimestamp":1774870518,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics(股票代码:BCAX)已正式启动其核心候选药物Fortifi-Hn01的关键性试验第三阶段。该阶段标志着药物研发进程中的重要里程碑,旨在进一步评估其在头颈癌治疗中的有效性与安全性。\n根据公司公布的时间表,该项试验的中期分析预计将于2027年中期完成。这一关键节点将为后续临床决策提供重要数据支持,并可能影响该疗法的最终审批路径。\nFortifi-Hn01作为Bicara Therapeutics研发管线中的重点产品,其第三阶段临床试验的推进备受业界关注。若最终结果符合预期,该药物有望为头颈癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162640845","title":"Bicara Therapeutics超额认购公开发行圆满收官,承销商全额行使额外购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1162640845","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162640845?lang=zh_cn&edition=fundamental","pubTime":"2026-02-27 05:30","pubTimestamp":1772141409,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics宣布其公开发行已正式完成,本次发行获得超额认购。承销商已全额行使购买额外股份的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614082484","title":"BUZZ-Bicara Therapeutics 募资 1.5 亿美元后股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2614082484","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614082484?lang=zh_cn&edition=fundamental","pubTime":"2026-02-25 21:02","pubTimestamp":1772024573,"startTime":"0","endTime":"0","summary":"BUZZ-Bicara Therapeutics 募资 1.5 亿美元后股价上涨2月25日 - ** Bicara Therapeutics BCAX.O股价在隔夜1.5亿美元的后续交易中盘前上涨4.2%,报16.93美元。(为便利非英文母语者,路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误,或未能包含所需语境,路透不保证自动化翻译文本的准确性,仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失,路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nL4S3ZL17J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1363072403.SGD","LU2089284900.SGD","LU1244550221.USD","LU1989772840.SGD","LU2089283258.USD","LU0106831901.USD","LU0234570918.USD","LU1162221912.USD","LU0106261372.USD","BK4139","BK4516","LU1791710582.SGD","BK4127","LU2271345857.HKD","LU1732799900.SGD","LU0795875169.SGD","LU1732800096.USD","LU0006306889.USD","LU1791710400.SGD","LU2023251221.USD","LU0912757837.SGD","LU1720051017.SGD","IE00BZ1G4Q59.USD","BK4504","LU1548497426.USD","LU2028103732.USD","LU2347655156.SGD","BCAX","LU0557290698.USD","LU0267386448.USD","LU2111349929.HKD","BK4581","LU1989772923.USD","LU2133065610.SGD","LU0320765646.SGD","LU2357305700.SGD","LU0528227936.USD","LU0795875086.SGD","LU1720051108.HKD","LU0314104364.USD","LU1244550577.SGD","IE00BKVL7J92.USD","LU1668664300.SGD","LU1244550494.USD","LU0882574139.USD","BK4585","BK4534","BK4588","LU0098860793.USD","LU0225283273.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134029809","title":"Bicara Therapeutics宣布1.5亿美元普通股及预付认股权证公开发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1134029809","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134029809?lang=zh_cn&edition=fundamental","pubTime":"2026-02-25 12:13","pubTimestamp":1771992810,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics已正式确定其1.5亿美元普通股及预付认股权证的公开发行价格。此次融资将支持公司推进其肿瘤治疗产品管线的临床开发。市场密切关注此次发行对公司未来发展的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132051680","title":"Ficerafusp Alfa 2000毫克Q2w方案在1L R/M HPV阴性头颈鳞癌中展现深度持久疗效 并支持开发更低频给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1132051680","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132051680?lang=zh_cn&edition=fundamental","pubTime":"2026-02-20 05:33","pubTimestamp":1771536793,"startTime":"0","endTime":"0","summary":"Ficerafusp Alfa采用2000毫克每两周给药方案,在治疗一线复发/转移性HPV阴性头颈部鳞状细胞癌患者时,展现出深度且持久的肿瘤缓解效果。该积极数据为进一步开发给药频率更低的治疗方案提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109954715","title":"Bicara Therapeutics计划开发Ficerafusp Alfa的负荷剂量与三周一次维持方案,待监管审批","url":"https://stock-news.laohu8.com/highlight/detail?id=1109954715","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109954715?lang=zh_cn&edition=fundamental","pubTime":"2026-02-20 05:33","pubTimestamp":1771536792,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. 宣布,公司计划为其在研药物Ficerafusp Alfa开发一种负荷剂量联合每三周一次维持给药的用药方案。该开发计划的推进,将取决于与监管机构达成一致意见。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}